CRECON MEDICAL ASSESSMENT

JP

Presentations

Presentation

  • Fukuda T, Akazawa M, Fukuda H, Igarashi A, Ikeda S, Ishida H, Kobayashi M, Moriwaki K, Noto S, Sakamaki H, Saito S, Shimozuma K, Shiroiwa T, Takura T, Tomita N. Proposal of economic evaluation guideline in Japan. ISPOR 16th Annual International Meeting. Dublin, Ireland. 2-6th November 2013.

  • Sakamaki H, Tajiri H, Inoue S. Cost-effectiveness Analysis of Capusule Endoscopy in Screening for Colorectal Cancer in Japan. ISPOR 16th Annual International Meeting. Dublin, Ireland. 2-6th November 2013.

  • Kamae I, Tatsunori M, Suman D, Yamabe K, Sugimoto T, Kobayashi M. The Survey of The Japan-Style Premium Scheme in Pharmaceutical Pricing Decisions. 16th ISPOR Annual European Congress, Dublin, Ireland. 2-6th November 2013.

  • Nakatani H, Shinohara H, Ito Y, Saruta T, Saito I, Inoue SKobayashi M. Health Economical Effect of Caduet (Amlodipine Besylate/Atorvastatin Calcium) on Patient with Hypertension and Dislipidemia. The 34th Annual scientific meeting of the Japanese Society of Hypertension.Utsunomiya, Tochigi. Oct 20th-22th 2011. (in Japanese)

  • Nakahara N, Kobayashi M, Mano T, Nakamura J. System Dynamics Simulation for Acute Schizophrenia Treatment. ISPOR 15th Annual International Meeting, 18 May, 2010, Atlanta, GA, USA.

  • Kobayashi M. The situation of Germany. ISPOR Japan Chapter 5th Annual Meeting. Tokyo, Japan, 13th March, 2010. (seminar “Use of pharmaceutical economic policy in foreign countries”) (in Japanese)

  • Kamae I, Kobayashi M. Value-based pricing of new drugs in Japan using the principle of incremental cost-effectiveness ratio. ISPOR 12th Annual European Congress, Paris, France.27 October, 2009.

  • Kamae I, Kobayashi M, Togawa D, Konno S. Cost-utility analysis of balloon kyphoplasty for patients with osteoporotic vertebral compression fractures in Japan. ISPOR 12th Annual European Congress, Paris, France. 24-27 October, 2009.

  • Ikeda S, Kobayashi M, Tajima N. Cost-effectiveness analysis of voglibose for prevention of type-2 diabetes mellitus in Japanese individuals with impaired glucose tolerance. ISPOR 12th Annual European Congress, Paris, France. 24-27 October, 2009.

  • Kobayashi M. The concept of health economic evaluation. The 47th Annual Congress of Japan Society for Healthcare Administration. 18 October, 2009, Tokyo, Japan. (ISPOR Japan Chapter Special Symposium “Medical policy making and health economics evaluation”). (in Japanese)

TOP
費用対効果分析

Cost-effectiveness analysis

To evaluate the cost-effectiveness of pharmaceuticals and medical devices by pharmacoeconomics (medical economic assessment), many specialized technologies and knowledge should be combined. We evaluate the cost-effectiveness of medical technologies using advanced modeling and statistical analysis technologies that we have developed over many years.

  • Cost-effectiveness analysis
  • Decision-making model construction
  • Review of previous studies
  • Systematic review
  • Indirect comparison/
    network meta-analysis
  • Budget impact analysis
    in the introduction of new pharmaceuticals
疾病負担分析

Burden of illness analysis

The socio-economic burden of disease is correlated with the therapeutic value of the disease. However, the estimation of such disease burdens is hardly done. We conduct burden of illness analysis to estimate epidemiological parameters, including the numbers of patients and events, long-term survival rates, and medical expenses.

  • Quantification of a target disease’s
    financial burden
  • Estimation and prediction of the number of patients
  • Estimation of lifetime medical expenses
  • Estimation of expected survival time
リアルワールドデータ

Real-world data/
Patient outcome data analyses

Real-world data, such as medical and receipt data, and patient outcome data are analyzed based on advanced statistical knowledge and technology.

  • Planning of survey/
    Development of protocols
  • Medical data analysis
  • Claims data analysis
  • QOL survey
  • Conjoint analysis/
    Discrete choice experiment (DCE)
  • Exploratory analysis
教育及び各種コンサルティング

Education
and other consulting services

We support in-house educational and enlightenment activities related to pharmacoeconomics (medical economic assessment) and health technology assessment (HTA), and provide consulting services. Furthermore, we provide consulting services based on review and summarization of technology appraisal (TA) by the UK’s National Institute for Health and Clinical Excellence (NICE).

  • Lecture/Workshop
  • Other consulting services
  • Review of NICE TA